Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to understand how the components of osteoarthritic knee joint fluid (synovial fluid) change after lavage treatment with platelet poor plasma. Additionally, the study participants will complete outcome questionnaire surveys before and after the treatment in conjunction with when synovial fluid is removed from the knee (2, 4, and 6 weeks after lavage). This data will help determine if the treatment of an osteoarthritic knee joint with platelet poor plasma lavage is a suitable stand-alone therapy or to improve outcome by preparing a patient's knee for further regenerative therapies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Platelet Rich Plasma Injections In Young And Old Human Subjects

NCT06451120

Osteoarthritis Articular Cartilage Musculoskeletal Disorders

RECRUITING PHASE2

Correlating the OA Knee Microenvironment to Outcomes After Regenexx-SD Treatment: A Multi-Site Study

NCT03898388

Knee Osteoarthritis

TERMINATED NA

Clinical Study of Pain Reduction by Peri-arthroscopic PRP Application in Knee Degeneration

NCT02189408

Knee Osteoarthritis Cartilage Damage Meniscal Tear

COMPLETED PHASE4

Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip

NCT02183896

Femoroacetabular Impingement Chondral Lesions

WITHDRAWN NA

Platelet Rich Plasma in Knee Osteoarthritis

NCT05080075

Knee Osteoarthritis

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to quantify the levels of catabolic markers in osteoarthritic (OA) knee synovial fluid microenvironment (ME) before lavage treatment with platelet poor plasma (PPP) and to determine whether the anti-catabolic capabilities of the PPP are sustainable or if the diseased synovial fluid returns to pre-lavage catabolic marker levels within the 6 week period of the study.

This data will be used to determine if treatment of a diseased (OA) knee with PPP lavage would be a suitable therapy for knee OA patients either as a stand-alone treatment or to improve outcome by preparing a patient's knee microenvironment for further treatment with cellular therapies. Incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score will be considered while determining these direct and indirect associations upon completion of the PPP lavage treatment. Correlation of subject reported clinical outcomes for the PPP lavage treatment will be evaluated to determine whether the treatment provides beneficial clinical outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Lavage with platelet poor plasma

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lavage with Platelet Poor Plasma (PPP)

Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect "washing out" the joint space.

Group Type EXPERIMENTAL

Lavage with Platelet Poor Plasma (PPP)

Intervention Type BIOLOGICAL

Lavage of 50cc PPP

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lavage with Platelet Poor Plasma (PPP)

Lavage of 50cc PPP

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\) Voluntary signature of the institutional review board approved Informed Consent
* 2\) Male or female ages 35-85
* 3\) Pain, swelling, and/or functional disability in the affected knee consistent with osteoarthritis in the knee joint
* 4\) Physical examination consistent with osteoarthritis as observed on imaging
* 5\) Unilateral or bilateral Kellgren-Lawrence grade 3 or greater knee osteoarthritis (moderate to severe OA) and/or diagnostic MRI imaging of the affected knee showing osteoarthritis (i.e. chondral loss, fissuring, defect, bone marrow lesion, meniscus tear, synovial thickening, etc…)
* 6\) Mild effusion upon ultrasound evaluation.
* 7\) Is independent, ambulatory, and can comply with all postoperative evaluations and visits

Exclusion Criteria

* 1\) Knee injections of any type within 3 months prior to the study.
* 2\) Knee surgery within 6 months prior to the study.
* 3\) Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)
* 4\) Quinolone or Statin induced myopathy/tendinopathy
* 5\) Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh
* 6\) Contraindications for MRI
* 7\) Condition represents a worker's compensation case
* 8\) Currently involved in a health-related litigation procedure
* 9\) Is pregnant
* 10\) Bleeding disorders
* 11\) Currently taking anticoagulant or immunosuppressive medication
* 12)Allergy or intolerance to study medication
* 13)Use of chronic opioid
* 14)Documented history of drug abuse within six months of treatment
* 15)Any other condition, that in the opinion of the investigator, that would preclude the patient from enrollment

Minimum Eligible Age

35 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No